MX2012007992A - Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874. - Google Patents

Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874.

Info

Publication number
MX2012007992A
MX2012007992A MX2012007992A MX2012007992A MX2012007992A MX 2012007992 A MX2012007992 A MX 2012007992A MX 2012007992 A MX2012007992 A MX 2012007992A MX 2012007992 A MX2012007992 A MX 2012007992A MX 2012007992 A MX2012007992 A MX 2012007992A
Authority
MX
Mexico
Prior art keywords
making
glutamate receptor
metabotropic glutamate
positive allosteric
receptor positive
Prior art date
Application number
MX2012007992A
Other languages
English (en)
Inventor
Alistair Boyd
Mark Richard Fielding
James Gair Ford
Lianne Frodsham
Michael D Golden
Kevin William Leslie
Ben Mckeever-Abbas
Paula Tomlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012007992A publication Critical patent/MX2012007992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Procesos para producir 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxa diazol-5-il)-2-(4-trifluorometoxibencil)-2,3-dihidroisoindol-1-on a.
MX2012007992A 2010-01-07 2011-01-04 Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874. MX2012007992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29301210P 2010-01-07 2010-01-07
PCT/SE2011/050002 WO2011084098A1 (en) 2010-01-07 2011-01-04 Process for making a metabotropic glutamate receptor positive allosteric modulator - 874

Publications (1)

Publication Number Publication Date
MX2012007992A true MX2012007992A (es) 2012-08-03

Family

ID=44305652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007992A MX2012007992A (es) 2010-01-07 2011-01-04 Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874.

Country Status (14)

Country Link
US (1) US20130203995A1 (es)
EP (1) EP2521722B1 (es)
JP (1) JP2013516462A (es)
KR (1) KR20120112749A (es)
CN (1) CN102791706A (es)
AU (1) AU2011203993A1 (es)
BR (1) BR112012016786A2 (es)
CA (1) CA2786327A1 (es)
DK (1) DK2521722T3 (es)
IL (1) IL220683A0 (es)
MX (1) MX2012007992A (es)
RU (1) RU2012134329A (es)
SG (1) SG181958A1 (es)
WO (1) WO2011084098A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525427A (ja) * 2010-04-30 2013-06-20 アストラゼネカ・アクチエボラーグ 代謝調節型グルタミン酸受容体ポジティブアロステリックモジュレーターの多形
US11123310B2 (en) 2017-02-24 2021-09-21 Pharmapotheca, Llc Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US9278904B2 (en) 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
US12208068B2 (en) 2013-12-31 2025-01-28 Pharmapotheca A Inc. Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
CN107935842A (zh) * 2017-12-27 2018-04-20 珠海奥博凯生物医药技术有限公司 一种2‑氯‑4‑溴‑6‑甲基苯甲酸的制备方法
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020180825A1 (en) 2019-03-02 2020-09-10 Chemapotheca, Llc Application for letters patent
CN110498783A (zh) * 2019-08-02 2019-11-26 成都蓝蜻蜓生物技术有限公司 一种合成罗沙司他中间体的方法
US12534428B2 (en) 2023-02-22 2026-01-27 Pharmapotheca A, Inc. Non-distillative process for manufacturing high purity amphetamines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2353151A1 (en) * 1998-12-16 2000-06-22 Boehringer Ingelheim Pharma Kg Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
JP5031745B2 (ja) * 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Also Published As

Publication number Publication date
DK2521722T3 (en) 2015-07-20
AU2011203993A1 (en) 2012-08-02
EP2521722B1 (en) 2015-05-06
EP2521722A4 (en) 2013-05-29
SG181958A1 (en) 2012-07-30
KR20120112749A (ko) 2012-10-11
BR112012016786A2 (pt) 2015-09-01
CN102791706A (zh) 2012-11-21
RU2012134329A (ru) 2014-02-20
WO2011084098A1 (en) 2011-07-14
JP2013516462A (ja) 2013-05-13
US20130203995A1 (en) 2013-08-08
CA2786327A1 (en) 2011-07-14
EP2521722A1 (en) 2012-11-14
IL220683A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
MX2012007992A (es) Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874.
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
MX2012012627A (es) Proceso para preparar linezolid.
HK1203497A1 (en) Non-systemic tgr5 agonists
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
IN2014CN02616A (es)
BR112012027628A2 (pt) polimorfos de um modulador alostérico positivo de receptor de glutamato metabotrópico
IL232917A (en) Annals of 5 - (3-aminophenyl) -5-alkyl-6,5-dihydro-2h [4,1] oxazin-3-amine
MX2014007202A (es) Lentes de contacto modificadas en la superficie.
GB201101517D0 (en) Receptor antagonists
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
ZA201404074B (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
IN2015DN00845A (es)
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
PH12015502477A1 (en) Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione
AP3531A (en) 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
PL2366517T3 (pl) Maszyna do wytwarzania produktów ceramicznych
ZA201401710B (en) "new administration regime for n-hydroxy-4-{-3-(n,n-dimethylamethyl)benzofurun-2 ylcarbonylamino]ethoxy}benzaminde"
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
UY34072A (es) Derivados sustituidos de indol
PH12013500210A1 (en) Highly crystalline valsartan
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
IL214916A0 (en) Process for preparaing 2,2 difluoroethylamine derivatives by imine hydrogenation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal